Back to News
Market Impact: 0.2
ARS Pharmaceuticals Reports Third Quarter 2026 Revenue of $37.7 million
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
ARS Pharmaceuticals reported third-quarter 2026 revenue of $37.7 million for the quarter ended September 30. Revenue included $33.4 million in U.S. net product revenue for neffy and $2.6 million in supply revenue; the provided article text is truncated before the remaining revenue details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
SPRY0.60
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?
- Equity Research Automation Statistics: A 2026 Evidence Check